Table 1.
Baseline patient, disease, and transplant characteristics
| All | Lower dose group | Higher dose group | p | |
|---|---|---|---|---|
| Patients | 395 | 197 | 198 | |
| Age* | 51.4 (20.7–69.4) | 52.4 (20.7–69.4) | 50.4 (20.7–66.8) | 0.043 |
| Male sex | 216 (54.7%) | 99 (50.3%) | 117 (59%) | 0.09 |
| Hematological disease | 0.13 | |||
| ALL-B/ALL-T | 52 (13.2%) | 23 (11.7%) | 29 (14.7%) | |
| AML/MDS | 199 (50.4%) | 111 (56.3%) | 88 (44.4%) | |
| MPN | 33 (8.3%) | 14 (7.1%) | 19 (9.6%) | |
| LPD | 111 (28.1%) | 49 (24.9%) | 62 (31.3%) | |
| Disease status at allo-HCT | 0.11 | |||
| CR | 265 (67.1%) | 140 (71.1%) | 125 (63.1%) | |
| Active disease | 130 (32.9%) | 57 (28.9%) | 73 (36.9%) | |
| EBMT score | 0.54 | |||
| Low risk | 154 (39%) | 82 (41.8%) | 72 (36.4%) | |
| Intermediate | 93 (23.5%) | 44 (22%) | 49 (24.7%) | |
| High | 148 (37.5%) | 71 (36.2%) | 77 (38.9%) | |
| Conditioning regimen | <.001 | |||
| MAC | 258 (65.3%) | 154 (78.2%) | 107 (54%) | |
| RIC | 137 (34.7%) | 43 (21.8%) | 91 (46%) | |
| Stem cell source | 0.56 | |||
| BM | 55 (13.9%) | 25 (12.7%) | 30 (15.15%) | |
| PB | 340 (86.1%) | 172 (87.3%) | 168 (84.85%) | |
| GVHD prophylaxis | 0.13 | |||
| CSA+ MTX | 372 (94.2%) | 190 (96.5%) | 182 (91.9%) | |
| CSA+ MMF | 23 (5.8%) | 7 (3.5%) | 16 (8.1%) | |
| Female to male D/R | 53 (13.4%) | 25 (12.7%) | 28 (14.1%) | 0.77 |
| HLA disparity | <.001 | |||
| No mismatch | 255 (64.6%) | 147 (74.6%) | 108 (54.5%) | |
| 1 HLA locus mismatch | 140 (35.4%) | 50 (25.4%) | 90 (45.5%) |
Values in bold are significant p values
*Median (range); otherwise, data are presented as number (%). ALL acute lymphoid leukemia, AML acute myeloid leukemia, CR complete remission, D/R donor/recipient, LPD lymphoproliferative disorders, MAC myeloablative conditioning, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasms, RIC reduced intensity conditioning, BM bone marrow, PB peripheral blood stem cells, CSA ciclosporin, MTX methotrexate, MMF mycophenolate mofetil